1.
Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, Fierro MT. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92(6):784-794; https://doi.org/10.3324/haematol.11127.